BMO Capital analyst Jim Birchenough reiterated an Outperform rating and $43 price target on OncoMed Pharmaceuticals (NASDAQ: OMED) as positive ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE